Veeva Systems is overvalued, with modest ~10% growth & high valuation multiples. Read why I recommend a sell rating on VEEV ...

KeyBanc lowered the firm’s price target on Veeva (VEEV) to $250 from $260 and keeps an Overweight rating on the shares. Into Q1 earnings, the ...

Veeva Systems experienced a 6% price increase last week, potentially propelled by its recent partnership with Flatiron Health. This collaboration aims to streamline clinical trial processes ...

Veeva Systems (VEEV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

There is veritable power in this. Enabling such a possibility is Veeva Commercial Cloud, which includes the Vault Platform, consisting of Content (PromoMats); Medical (MedComms, MedInquiry); CRM ...

As part of the partnership, Flatiron Health will join the Veeva Product Partner Program. Flatiron and Veeva customers utilizing Flatiron Clinical Pipe™ will benefit from accelerated deployment ...

The latest trading session saw Veeva Systems (VEEV) ending at $222.72, denoting a -0.42% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a loss of 0.17% ...